​

Aquestive Therapeutics (AQST) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Aquestive Therapeutics Revenue Highlights

Latest Revenue (Y)

$44.55M

Latest Revenue (Q)

$10.00M

Main Segment (Y)

Manufacture and Supply Revenue

Main Geography (Y)

UNITED STATES

Aquestive Therapeutics Revenue by Period

Aquestive Therapeutics Revenue by Year

DateRevenueChange
2025-12-31$44.55M-22.61%
2024-12-31$57.56M13.80%
2023-12-31$50.58M6.09%
2022-12-31$47.68M-6.20%
2021-12-31$50.83M10.87%
2020-12-31$45.85M-12.85%
2019-12-31$52.61M-21.98%
2018-12-31$67.43M0.77%
2017-12-31$66.92M29.22%
2016-12-31$51.78M-

Aquestive Therapeutics generated $44.55M in revenue during NA 2025, up -22.61% compared to the previous quarter, and up 97.16% compared to the same period a year ago.

Aquestive Therapeutics Revenue by Quarter

DateRevenueChange
2025-06-30$10.00M14.71%
2025-03-31$8.72M-26.52%
2024-12-31$11.87M-12.37%
2024-09-30$13.54M-32.62%
2024-06-30$20.10M66.76%
2024-03-31$12.05M-8.73%
2023-12-31$13.21M1.57%
2023-09-30$13.00M-1.80%
2023-06-30$13.24M18.92%
2023-03-31$11.13M4.23%
2022-12-31$10.68M-6.81%
2022-09-30$11.46M-13.58%
2022-06-30$13.27M8.11%
2022-03-31$12.27M10.76%
2021-12-31$11.08M-16.63%
2021-09-30$13.29M-13.41%
2021-06-30$15.35M37.97%
2021-03-31$11.12M55.57%
2020-12-31$7.15M-13.45%
2020-09-30$8.26M-61.89%
2020-06-30$21.68M147.29%
2020-03-31$8.77M-46.62%
2019-12-31$16.42M32.22%
2019-09-30$12.42M11.58%
2019-06-30$11.13M-11.98%
2019-03-31$12.64M-24.85%
2018-12-31$16.82M26.81%
2018-09-30$13.27M-4.75%
2018-06-30$13.93M-40.51%
2018-03-31$23.41M91.97%
2017-12-31$12.20M-55.08%
2017-09-30$27.15M143.64%
2017-06-30$11.14M-32.21%
2017-03-31$16.44M-

Aquestive Therapeutics generated $10.00M in revenue during Q2 2025, up 14.71% compared to the previous quarter, and up 82.99% compared to the same period a year ago.

Aquestive Therapeutics Revenue Breakdown

Aquestive Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
License and Royalty Revenue$3.52M$15.35M$5.38M$2.35M$5.38M
Manufacture and Supply Revenue$40.23M$39.98M$43.80M$36.38M$35.31M
Co-Development and Research Fees$1.28M$1.93M$1.40M$1.29M$1.64M
Proprietary Product Sales---$7.66M$8.51M
Royalty---$-916.00K$-1.10M

Aquestive Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Manufacture and Supply Revenue (89.34%), License and Royalty Revenue (7.82%), and Co-Development and Research Fees (2.84%).

Quarterly Revenue by Product

Product/ServiceDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20
Co-Development and Research Fees$181.00K$302.00K$378.00K$418.00K$1.03M$492.00K$403.00K$335.00K$490.00K$124.00K$453.00K$254.00K$395.00K$241.00K$403.00K$218.00K$523.00K$456.00K$394.00K-
License and Royalty Revenue$852.00K$1.04M$839.00K$790.00K$12.05M$2.16M$1.13M$1.87M$1.10M$1.48M$919.00K$917.00K$376.00K$552.00K$506.00K$380.00K$328.00K$2.36M$373.00K-
Manufacture and Supply Revenue$11.98M$11.47M$9.58M$7.19M$18.79M$10.67M$10.52M$11.00M$11.41M$11.64M$9.76M$8.92M$8.41M$9.87M$9.17M$7.69M$10.45M$10.66M$6.51M$4.80M
Manufactured Product, Other--$-797.00K$319.00K$217.00K---------------
Proprietary Product Sales-----------$589.00K$2.28M$2.60M$2.19M$2.79M$1.99M$1.91M$1.58M-
Royalty-----------$-13.00K$-25.00K-------

Aquestive Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Manufacture and Supply Revenue (92.06%), License and Royalty Revenue (6.55%), and Co-Development and Research Fees (1.39%).

Aquestive Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 25Dec 24Dec 23Dec 22Dec 21
Non-US$14.94M$17.63M$13.48M$7.76M$7.97M
UNITED STATES$29.60M$39.93M$37.10M$39.92M$42.86M

Aquestive Therapeutics's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (66.46%), and Non-US (33.54%).

Quarterly Revenue by Country

CountryDec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Dec 20Dec 19
UNITED STATES$9.39M$10.12M$4.89M$5.20M$18.98M$10.53M$10.43M$11.73M$9.89M$7.31M$8.16M$8.51M$9.08M$11.26M$11.08M$9.37M$10.53M$13.11M--
Non-US$3.63M$2.68M$5.11M$3.52M$12.99M$3.01M$1.63M$1.47M$3.11M$5.93M$2.97M$2.18M$2.38M$2.01M$1.19M$1.71M$2.76M$2.24M$1.69M$1.81M
United States------------------$5.46M$14.61M

Aquestive Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (72.14%), and Non-US (27.86%).

Aquestive Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
SNDLSNDL$909.01M$197.75M
EBSEmergent BioSolutions$742.90M$231.10M
ESPREsperion Therapeutics$403.13M$87.31M
ARVNArvinas$262.60M$41.90M
SIGASIGA$94.60M$2.62M
AQSTAquestive Therapeutics$44.55M$10.00M
DRIODarioHealth$27.04M$5.01M
AVXLAnavex Life Sciences--
MLTXMoonLake Immunotherapeutics--
OFIXOrthofix Medical-$205.63M
ERASErasca--

AQST Revenue FAQ

What is Aquestive Therapeutics’s yearly revenue?

Aquestive Therapeutics's yearly revenue for 2025 was $44.54M, representing a decrease of -22.61% compared to 2024. The company's yearly revenue for 2024 was $57.56M, representing an increase of 13.80% compared to 2023. AQST's yearly revenue for 2023 was $50.58M, representing an increase of 6.09% compared to 2022.

What is Aquestive Therapeutics’s quarterly revenue?

Aquestive Therapeutics's quarterly revenue for Q2 2025 was $10M, a 14.71% increase from the previous quarter (Q1 2025), and a -50.23% decrease year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $8.72M, a -26.52% decrease from the previous quarter (Q4 2024), and a -27.65% decrease year-over-year (Q1 2024). AQST's quarterly revenue for Q4 2024 was $11.87M, a -12.37% decrease from the previous quarter (Q3 2024), and a -10.14% decrease year-over-year (Q4 2023).

What is Aquestive Therapeutics’s revenue growth rate?

Aquestive Therapeutics's revenue growth rate for the last 3 years (2023-2025) was -11.94%, and for the last 5 years (2021-2025) was -12.37%.

What are Aquestive Therapeutics’s revenue streams?

Aquestive Therapeutics's revenue streams in c 25 are License and Royalty Revenue, Manufacture and Supply Revenue, and Co-Development and Research Fees. License and Royalty Revenue generated $3.52M in revenue, accounting 7.82% of the company's total revenue, down -77.07% year-over-year. Manufacture and Supply Revenue generated $40.22M in revenue, accounting 89.34% of the company's total revenue, up 0.62% year-over-year. Co-Development and Research Fees generated $1.28M in revenue, accounting 2.84% of the company's total revenue, down -33.56% year-over-year.

What is Aquestive Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Aquestive Therapeutics was Manufacture and Supply Revenue. This segment made a revenue of $40.22M, representing 89.34% of the company's total revenue.